• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Effect of a Single Bolus Injection of Low-Dose Hydrocortisone for Prevention of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation
【24h】

Effect of a Single Bolus Injection of Low-Dose Hydrocortisone for Prevention of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation

机译：单剂小剂量氢化可的松注射液预防射频消融后房颤复发的效果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: ?The transient use of corticosteroid shortly after atrial fibrillation (AF) ablation might prevent immediate and mid-term AF recurrence; however, the effective dosage for preventing AF recurrence has not been determined. In this study, we evaluated whether low-dose hydrocortisone is effective for the prevention of AF recurrence after radiofrequency catheter ablation (RFCA). Methods and Results: ?We enrolled 89 AF patients (70 males, 55.8±10.9 years) who underwent RF ablation and were treated with single bolus injection of 100mg hydrocorticosteroid (corticosteroid group). For the control group, we enrolled 120 sex- and age-matched AF patients (94 males, 55.4±10.5 years). Pericarditis occurred in 3 (2.5%) and 1 (1.1%) patients in the control and corticosteroid groups, respectively. The number of patients with immediate AF recurrence (≤2 days) was 17 (14.5%) and 11 (12.4%) in the control and steroid groups, respectively (P=0.687). Treatment with low-dose steroid did not decrease early (3–30 days) AF recurrence (13 [11.1%] vs. 11 [12.5%], P=0.829) or late (≥31 days) AF recurrence after ablation (26 [22.2%] vs. 13 [14.6%], P=0.209). There was no difference in cumulative survival free of late AF recurrence between the corticosteroid and control groups (P=0.57 by log-rank test). White blood cell count, C-reactive protein concentration and maximum body temperature also were unchanged by low-dose steroid. Conclusions: ?Single bolus injection of low-dose hydrocortisone after AF ablation is not effective for preventing AF recurrence during the mid-term follow-up period.??(Circ J?2013; 77: 53–59)
机译：背景：？房颤消融后不久即短暂使用皮质类固醇可能会阻止即刻和中期房颤复发。然而，尚未确定预防房颤复发的有效剂量。在这项研究中，我们评估了小剂量氢化可的松对射频导管消融（RFCA）后房颤复发是否有效。方法和结果：我们招募了89例接受射频消融的AF患者（70例男性，55.8±10.9岁），并单次推注100mg糖皮质激素治疗（皮质类固醇组）。对于对照组，我们招募了120名性别和年龄相匹配的房颤患者（94名男性，55.4±10.5岁）。对照组和皮质类固醇组分别发生3例（2.5％）和1例（1.1％）的心包炎。在对照组和类固醇组中，即刻AF复发（≤2天）的患者分别为17例（14.5％）和11例（12.4％）（P = 0.687）。消融后低剂量类固醇治疗并没有减少早期（3-30天）AF复发（13 [11.1％] vs. 11 [12.5％]，P = 0.829）或晚期（≥31天）AF复发（26 [ 22.2％] vs. 13 [14.6％]，P = 0.209）。皮质类固醇和对照组之间的无AF晚期复发的累积生存率无差异（按log-rank检验，P = 0.57）。低剂量类固醇也不会改变白细胞计数，C反应蛋白浓度和最高体温。结论：？房颤消融后单次推注小剂量氢化可的松不能有效预防中期随访期间房颤的复发。（Circ J？2013; 77：53-59）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号